What You Should Know:
- Vivalink, a leading provider of digital healthcare solutions, has expanded its Biometrics Data Platform - which delivers uninterrupted streams of real-world physiological data - to enable faster algorithm development for disease detection and diagnosis.
- More than 100 digital healthcare application companies and customers in 32 countries are already developing a wide range of medical applications for remote patient monitoring and clinical trials based on the
Read More
Clinical Trials | News, Analysis, Insights - HIT Consultant
PathAI and GlaxoSmithKline Partner to Accelerate Research and Drug Development
What You Should Know:
- PathAI and GSK announced a multi-year strategic artificial intelligence (AI) partnership today with a focus on accelerating research and- building drug development programs in oncology and non-alcoholic steatohepatitis (NASH).
- As part of the partnership, GSK will leverage both PathAI’s expertise and models to advance GSK’s proprietary AI models and focus on designing better models to deliver improved treatment options for patients with cancer
Read More
Viz.ai Raises $100M for Care Coordination Platform at $1.2B Valuation
What You Should Know:
- Viz.ai, a San Francisco-based AI-powered disease detection and care coordination platform raises $1000M in Series D funding led by Tiger Global and Insight Partners. The round also included participation from Scale Ventures, Kleiner Perkins, Threshold, GV (formerly Google Ventures), Sozo Ventures, CRV, and Susa.
- The new funds will be used to support Viz.ai’s significant growth trajectory, expand the Viz Platform to detect
Read More
C2i Genomics Brings Distributed Cancer Monitoring to Cancer Centers Across Europe
What You Should Know:
- C2i Genomics, a cancer intelligence company launches its C2inform minimal residual disease (MRD) test across Europe, after obtaining CE-IVD marking in the EU, UK and Switzerland. The company also announced the completion of several clinical trials across the globe, including leading cancer centers in Europe, U.S. and Singapore.
- The new clinical data will be presented at the 2022 American Association for Cancer Research (AACR) annual meeting in New Orleans,
Read More
Labcorp & Medidata to Co-Develop Digital Biomarkers & Expand Decentralized Clinical Trials
What You Should Know:
- Medidata, a Dassault Systèmes company, today announced that Labcorp, a leading global life sciences company, has selected Medidata's technology platform to extend their 14-year partnership, the foundation of their initiative to co-develop digital biomarkers and expand the use and functionality of decentralized clinical trials. Labcorp Drug Development has developed its offerings on Medidata technologies, starting with Rave EDC
Read More
VivoSense Raises $25M for Wearable Sensor Biomarkers to Advance Clinical Trials
What You Should Know:
- VivoSense, an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data raises $25 Million in Series A funding.
- The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments. VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital
Read More
COTA Promotes Miruna Sasu to President and CEO
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company, announced today that Miruna Sasu, Ph.D., MBA, has been appointed president and chief executive officer.
- Since April 2021 when she was hired as the company’s chief strategy officer, Miruna has helped spearhead a series of research collaborations focused on investigating racial disparities in cancer care and the drug development process, including partnerships with the University of Chicago
Read More
Tempus Launches Pathology-Driven AI Platform
What You Should Know:
- Tempus, a provider of artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide.
- With access to over 50 petabytes of de-identified multimodal data, Tempus is developing AI models with the aim to identify patients who would
Read More
Applied XL Raises $3.5M for Real-Time Data Tracking Platform
What You Should Know:
- Applied XL, a real-time information company tracking disruptions to the health of people, places, and the planet, today announced it had raised $3.5 million in seed funding led by Hearst Ventures with the participation of the Boston Globe Media Partners and STAT, which are owned by the Henry family.
- The latest round brings Applied XL’s total funds raised to date to $5 million in the last 12 months. The company will use the new funding to scale its first vertical
Read More
Day 3 HIMSS Roundup: Glooko Acquires DIABNEXT, GE Healthcare/AliveCor Integration
Venture Capital, Private Equity, Mergers & Acquisitions (M&A) Activity
Glooko Acquires DIABNEXT® to Expand Diabetes Offerings in France
Glooko, a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the acquisition of DIABNEXT, a Paris-based company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers, so they can
Read More
